# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Jessica Tassan reiterates Oscar Health (NYSE:OSCR) with a Overweight and maintains $28 price target.
Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and raises the price target from $...
Adjusted EBITDA to be in the $160 million to $210 million range, $35 million higher than the prior range of $125 million to $17...
Oscar Health (NYSE:OSCR) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 2...